To our knowledge, this study is the first to report 4HPR’s competitive inhibition of two kinases (JAK1 and CK2) that are integral for IL6-mediated carcinogenesis and to confirm the in vivo cancer-preventive efficacy of JNP-mediated local delivery of 4HPR and TCZ. This evidence concerns the gene IL6 and cancer.